TAIKO PHARMACEUTICAL CO.,LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 368 JPY | +0.27% |
|
-2.13% | +21.45% |
| Sales 2022 | 5.04B 32.02M | Sales 2023 | 6.12B 38.88M | Capitalization | 15.08B 95.82M |
|---|---|---|---|---|---|
| Net income 2022 | -4.9B -31.1M | Net income 2023 | -3.61B -22.94M | EV / Sales 2022 | 3.47 x |
| Net Debt 2022 | 304M 1.93M | Net cash position 2023 | 2.23B 14.17M | EV / Sales 2023 | 2.1 x |
| P/E ratio 2022 |
-3.51
x | P/E ratio 2023 |
-3.97
x | Employees | 208 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 60.75% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.27% | ||
| 1 week | -2.13% | ||
| 1 month | +4.55% | ||
| 3 months | +15.36% | ||
| 6 months | +22.26% | ||
| Current year | +21.45% |
1 week
355.00
378.00
1 month
345.00427.00
Current year
285.00427.00
1 year
263.00427.00
3 years
263.001 086.00
5 years
263.002 928.00
10 years
263.002 928.00
| Managers | Title | Age | Since |
|---|---|---|---|
Takashi Shibata
PSD | President | 67 | 98-11-30 |
Hitoshi Shibata
CHM | Chairman | 73 | 77-04-30 |
Tsuyoshi Honma
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hitoshi Shibata
CHM | Chairman | 73 | 77-04-30 |
Takashi Shibata
PSD | President | 67 | 98-11-30 |
Masaji Hashimoto
BRD | Director/Board Member | 56 | 20-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 19 M€ | +11.22% | ||
| 0.00% | 17 M€ | +14.54% | - | |
| 0.00% | 140,441 M€ | +19.22% | ||
| 0.00% | 63,295 M€ | +18.52% | - | |
| 0.00% | 20,360 M€ | +16.70% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 368 | +0.27% | 144,000 |
| 24-05-30 | 367 | +1.38% | 273,700 |
| 24-05-29 | 362 | -2.95% | 212,000 |
| 24-05-28 | 373 | -.--% | 161,200 |
| 24-05-27 | 373 | -0.80% | 145,600 |
Delayed Quote Japan Exchange, May 31, 2024 at 02:00 am EDT
More quotes
TAIKO PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company. The Company is engaged in three business segments. The Pharmaceutical Product segment is engaged in the manufacturing, sales and export of gastrointestinal drugs under the name SEIROGAN, SEIROGAN TOI-A (sugar coated tablet) and PISHUT. The Infection Control segment is engaged in the planning, development and sales of infection control products, which apply proprietary technique regarding chlorine dioxide gas. The Others segment is engaged in the manufacturing and sales of bath liquid, soap and gardening pyroligneous acid.
Sector
Pharmaceuticals
Calendar
2024-08-08
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +21.45% | 117M | |
| +15.91% | 41.97B | |
| +22.40% | 22.34B | |
| +18.48% | 15.25B | |
| +16.12% | 14B | |
| +45.12% | 12.06B | |
| -0.05% | 6.79B | |
| -9.58% | 6.8B | |
| -8.87% | 5.73B | |
| +14.18% | 5.49B |
- Stock Market
- Equities
- 4574 Stock
